Exhibit 99.1 FOR IMMEDIATE RELEASE BAXTER REPORTS FIRST-QUARTER 2024 RESULTS DEERFIELD, Ill., MAY 2, 2024 – Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the first quarter of 2024. "Baxter's results in the first quarter reflect the company's solid operational performance, fueled by the benefits being realized from our ongoing strategic transformation initiatives, including our new operating model structure, and continued strong execution across our integrated supp ...

Analysts on Wall Street project that Baxter International (BAX) will announce quarterly earnings of $0.61 per share in its forthcoming report, representing an increase of 3.4% year over year. Revenues are projected to reach $3.55 billion, declining 2.7% from the same quarter last year.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Prior to a ...

Baxter International, Inc. (BAX) recently announced the expansion of its Pharmaceutical portfolio with the launch of five injectable products in the United States.The launched products are likely to provide ready-to-use formulations that promote patient needs in key therapeutic areas and benefit healthcare professionals with additional convenience.Price PerformanceIn the past six months, BAX’s shares have rallied 32.3% compared with the industry’s rise of 21.7%. The S&P 500 has gained 19.1% in the same time ...

The Zacks Medical sector is facing headwinds in the form of inflation, higher interest rates, supply-chain disruptions and high operating costs. These factors are likely to put pressure on the industry players’ margin.Amid these ongoing headwinds, the sector has gained 2.5% until Apr 9, underperforming the S&P 500 Index’s 9.4% gain.Meanwhile, amid the rising risk of a downtrend in the market, it would be a wise decision to invest in some dividend-paying companies like Cardinal Health (CAH) , Baxter Internat ...

Baxter International (BAX) is poised for growth, given the demand for its medically essential products, coupled with transformational actions. However, inflationary pressure remains a concern.Shares of this Zacks Rank #3 (Hold) company have gained 10.8% year to date compared with the industry's 5.3% growth. The S&P 500 Index has increased 9.4% in the same time frame.BAX, with a market capitalization of $21.46 billion, is a global medical technology company providing items such as kidney-dialysis equipment, ...

Baxter International Inc. (BAX) recently received the FDA’s 510(k) clearance for its Novum IQ large volume infusion pump (LVP) with Dose IQ Safety Software. Adding LVP modality to the Novum IQ Infusion Platform, which includes Baxter’s syringe infusion pump (SYR) with Dose IQ Safety Software, powered by the IQ Enterprise Connectivity Suite, is expected to enable clinicians to utilize a single, integrated system across a variety of patient care settings.Baxter expects to expand the platform in the future via ...

monsitj In this article, I will outline why I think Baxter International Inc. (NYSE:BAX) is a buy. BAX is a member of the health care industry and sells health care equipment. While not a factor in my analysis, BAX is expected to see double-digit earnings per share growth over the next three years, which is attractive. My technical analysis will focus on price action, momentum, volume, and relative strength using a weekly time frame. I will also mention the importance of risk management in this article, ...

Core Insights - Spectral Medical Inc. has achieved a significant milestone by reaching its Interim Enrollment target of 90 patients in the TIGRIS trial, which is crucial for the development of its product PMX for treating septic shock [1][2] - Baxter International has the option to make a second milestone payment to Spectral to maintain its exclusive distribution rights for PMX following this enrollment milestone [1] Company Overview - Spectral is a late-stage theranostic company focused on advancing therapeutic options for sepsis and septic shock, with its product Toraymyxin™ (PMX) being a therapeutic hemoperfusion device that removes endotoxin from the bloodstream [3] - PMX is already approved for therapeutic use in Japan and Europe, having been safely and effectively used on over 340,000 patients [3] - The company has exclusive development and commercial rights for PMX in the U.S. since March 2009 and signed an exclusive distribution agreement for Canada in November 2010 [3] TIGRIS Trial Details - The TIGRIS trial is a confirmatory study comparing PMX in addition to standard care against standard care alone, designed as a 2:1 randomized trial involving 150 patients [4] - The trial employs Bayesian statistics to analyze the results, which is a novel approach in sepsis trials [4]

Core Viewpoint - Baxter International Inc. has declared a quarterly cash dividend of $0.29 per share, indicating a strong commitment to returning value to shareholders [1]. Group 1: Dividend Announcement - The quarterly cash dividend of $0.29 per share is payable on April 1, 2024, to stockholders of record as of March 1, 2024 [1]. - The indicated annual dividend rate is $1.16 per share of common stock [1]. Group 2: Company Overview - Baxter operates in the healthcare sector, providing a wide range of products including diagnostic, critical care, kidney care, nutrition, hospital, and surgical products [2]. - The company has been in operation for over 90 years, focusing on innovations that save and sustain lives [2]. - Baxter's products and digital health solutions are available in more than 100 countries, highlighting its global reach and commitment to advancing healthcare innovations [2].

Core Viewpoint - Baxter International Inc. reported better-than-expected adjusted earnings per share (EPS) for the fourth quarter of 2023, but the stock experienced a decline in pre-market trading despite the positive results [1][2]. Financial Performance - Adjusted EPS from continuing operations was 88 cents, exceeding the Zacks Consensus Estimate of 86 cents by 2.3% and improving 13% year-over-year [1]. - Total revenues from continued operations reached $3.89 billion, reflecting a 4% increase on a reported basis and 3% at constant currency, surpassing the Zacks Consensus Estimate by 2.4% [2]. - For the full year 2023, Baxter recorded total revenues of $14.81 billion, up 2% year-over-year, while adjusted EPS from continuing operations was $2.60, down 14% from the previous year [9]. Segment Performance - The Medical Products & Therapies segment generated sales of $1.32 billion, up 6% year-over-year [4]. - Infusion Therapies and Technologies sales totaled $1.04 billion, increasing by 5% year-over-year, while Advanced Surgery sales reached $278 million, up 7% [5]. - The Healthcare Systems and Technologies segment reported sales of $795 million, an 8% increase year-over-year [6]. - The Pharmaceuticals segment's sales were $596 million, up 8% year-over-year [6]. - The Kidney Care segment saw total sales of $1.16 billion, down 1% year-over-year, with Chronic Therapies sales at $950 million, down 2% [7]. Margin Analysis - Adjusted gross profit for the fourth quarter was $1.63 billion, a 5.7% increase year-over-year, with a gross margin improvement of 80 basis points to 42% [8]. - Adjusted operating income from continuing operations was $449 million, up 13% year-over-year, with an operating margin improvement of 90 basis points to 11.6% [8]. Future Guidance - For Q1 2024, Baxter anticipates sales growth of approximately 1% on a reported basis, with adjusted EPS expected between 59 cents and 62 cents [10]. - For the full year 2024, sales growth is projected to be nearly 2% on a reported basis, with adjusted EPS expected in the range of $2.85 to $2.95 [10].